ライフサイエンスコーパス: clinical

1 Their clinical activity has been correlated with activated T-c

2 ly infected cells will soon allow measurable clinical advances toward an HIV cure.

3 glass/week had significantly lower risk for clinical AL progression than non-drinkers (RR = 0.52; 95

4 ide critical assessments of disease for both clinical and basic science imaging research studies.

5 phy, the goal of this study was to develop a clinical and biomarker score to predict the presence of

6 vide incremental prognostic information over clinical and conventional echocardiographic characterist

7 The clinical and electroencephalographic features of a canin

8 Our clinical and experimental data suggest a correlation bet

9 A. actionmycetemcomitans Ltx with respect to clinical and inflammatory findings in individuals with o

10 gnosis emphasises the importance of thorough clinical and laboratory evaluations to exclude secondary

11 Updated survival data were correlated with clinical and molecular factors, and patterns of postprot

12 To describe the detailed clinical and molecular genetic findings in a series of p

13 This pilot study, integrating clinical and molecular-based techniques, begins to eluci

14 These findings provide key clinical and preclinical relevance to the conformational

15 et with chamber operators to list technical, clinical and regulatory unmet needs as well as the prere

16 ases (IBD), and study their association with clinical and serologic features.

17 ne and three patients subsequently developed clinical and virological relapses.

18 (AUDIT), and self-reported help-seeking from clinical and welfare providers comparing those receiving

19 ciation between early death and demographic, clinical, and socioeconomic factors.

20 emonstrate an association between ketamine's clinical antidepressant effects and circadian timekeepin

21 The primary objective was to demonstrate the clinical applicability of ZTE in osseous shoulder imagin

22 ith age throughout childhood, limiting their clinical applicability.

23 To investigate the clinical application of targeting JAK for ALK- ALCL, we

24 utoregulation, measurement methodologies and clinical applications in stroke to help build a consensu

25 spensable tool for many biotechnological and clinical applications.

26 filing of tumors is emerging as an important clinical approach.

27 external validation cohorts and compared to clinical assessment alone.

28 Each case was read prospectively for clinical assessment and to establish ground truth.

29 at PVP may be useful in the standard bedside clinical assessment of volume status in these patients t

30 , plaque index (PI), probing depth (PD), and clinical attachment level (CAL).

31 More severe clinical attachment loss (CAL) was observed in the 3D RS

32 h immediate implications, given the existing clinical availability of complement antagonists.

33 itoring, and to promote its translation into clinical bedside practice for stroke management.

34 0.95 per extra year, 0.93-0.98; p<0.001) and clinical benefit (OR 0.95 per extra year, 0.92-0.98; p=0

35 therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metas

36 mmendations, suggest different constructs of clinical benefit measured.

37 coagulation outweighs the bleeding risk (net clinical benefit) has been shown to be approximately 1%

38 These studies demonstrated the clinical benefits of nepafenac 0.3% over vehicle in redu

39 anti-EBOV EC50 = 86 nM in macrophages as the clinical candidate.

40 sactivation domain have emerged as bona fide clinical candidates for reactivating the tumor suppressi

41 olyunsaturated fatty acid supplementation on clinical cardiovascular events, we update prior recommen

42 (POCT) for respiratory viruses might improve clinical care by reducing unnecessary antibiotic use, sh

43 y guideline provides recommendations for the clinical care of adult patients with astrocytic and olig

44 ence exists to support its use over standard clinical care.

45 ele for Braf(V600E) , a mutation observed in clinical cases of GIST, we observed that Braf(V600E) act

46 0.683 for ADA fasting glucose concentration clinical categories and 0.688 for ADA HbA1c clinical cat

47 0.701 for ADA fasting glucose concentration clinical categories and 0.722 for ADA HbA1c clinical cat

48 clinical categories and 0.688 for ADA HbA1c clinical categories for all-cause mortality.

49 entration categories and 0.672 for ADA HbA1c clinical categories for atherosclerotic cardiovascular d

50 clinical categories and 0.722 for ADA HbA1c clinical categories for peripheral arterial disease, and

51 oal of this study was to further explore the clinical characteristics and survival of patients with A

52 ive cytokine profiling data across different clinical characteristics are lacking.

53 -/-) pig is a large-animal model of HT1 with clinical characteristics that resemble the human phenoty

54 prevalence in epilepsy (APE) score based on clinical characteristics was assigned prospectively.

55 associations with different definitions and clinical complications can inform the comparative value

56 tatistics were 0.662 for ADA fasting glucose clinical concentration categories and 0.672 for ADA HbA1

57 non-motor symptoms in PD and have important clinical consequences, including therapeutics.

58 often overlooked; yet data suggest that the clinical context in which hyperkalemia develops is at le

59 Clinical Context The treatment goal for CRPC is palliati

60 plastic surgeons to continue its use in this clinical context.

61 onsidered as a useful strategy for achieving clinical control of asthma in obese patients.

62 ective longitudinal study was conducted in a clinical convenience sample of 80 mother-child dyads.

63 generally inferred by [Hb] measurements and clinical correlates remains unclear.

64 of solid-cystic pituitary masses along with clinical correlation, which includes early involvement o

65 gressive lymphoma is a critical event in the clinical course of follicular lymphoma (FL) patients.

66 Progressive clinical course was observed in 45%, carotidodynia in 10

67 In-hospital mortality using clinical criteria declined (-3.3%/y [95% CI, -5.6% to -1

68 Baseline clinical data and GEP class assignments were obtained.

69 We investigated the clinical data and sera of 722 participants in the German

70 acteristics, medical history and HIV-related clinical data were collected.

71 Postmortem tissue and clinical data were provided by the Oregon Health and Sci

72 se challenges for diagnosis, treatments, and clinical decision making.

73 Clinical decision rules can help to determine the need f

74 after, provider overrides of evidence-based clinical decision support (CDS) for ordering computed to

75 impact on response to ibrutinib, may inform clinical decisions, and should be evaluated in larger da

76 the final cell counts are commonly used for clinical decisions.

77 er-associated mortality, and there are unmet clinical demands for the discovery of new biomarkers and

78 Clinical demands, funding challenges, and other factors

79 Hippocampal volume loss is a hallmark of clinical depression.

80 After clinical deterioration using meropenem monotherapy, trea

81 coccal meningitis (CM) frequently experience clinical deterioration, known as cryptococcosis-associat

82 , consciousness level, and other evidence of clinical deterioration.

83 Patients with a clinical diagnosis of obstructive HCM referred for surgi

84 identified as hallmarks that correlated with clinical disease progression.

85 and after 5 months of challenge without any clinical disease.

86 Compared with temozolomide, a clinical DNA-alkylating agent against glioma, 6OTD requi

87 immense diversity coupled with differential clinical effects of this diversity suggest that an effec

88 NMDAR) channel-blocking drugs with divergent clinical effects.

89 ate protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therap

90 rms were not the same, neither mortality nor clinical efficacy was reported, only pharmacokinetic or

91 ment; however, the study was not powered for clinical efficacy.

92 , a constellation of compatible demographic, clinical, endoscopic, and histologic findings establish

93 We investigated the clinical epidemiology of all human cases of LA-MRSA CC39

94 ine strategies have advanced to the stage of clinical evaluation with unprecedented speed.

95 , or low pretest probability of CDI based on clinical evaluation, laboratory, and imaging results.

96 Preclinical and preliminary clinical evidence indicates that radiolabeled somatostat

97 Complete post-operative clinical examination and history were obtained, and tran

98 Clinical examination revealed laxity of the left abdomin

99 servational studies from the past 7 years of clinical experience in Europe.

100 hat echinocandin therapy altered the risk of clinical failure.

101 ernationally recognized leaders in basic and clinical FBD research.

102 Their clinical features and HRCT findings were investigated to

103 The clinical features and the results of the complementary t

104 on for approval of asthma therapies, but the clinical features of exacerbation-prone asthma (EPA) rem

105 The clinical features of SDHA, TMEM127, MAX, and SDHAF2 dise

106 We reviewed the presenting clinical features, the pre-API and post-API investigatio

107 The dominant clinical finding is an orthostatic headache.

108 more aggressive subtype that warrants closer clinical follow-up.

109 ; and retinal structural changes observed on clinical funduscopy as well as by pseudocolor, autofluor

110 Societies principles for the development of clinical guidelines as the framework for guideline devel

111 recently shown to have prognostic value for clinical HD progression and brain atrophy.

112 No alternative explanation for clinical hemolysis was found.

113 strongest association with these features of clinical heterogeneity in synucleinopathies.

114 usceptibility to atherosclerosis, provides a clinical human model that can be utilized to investigate

115 ty: a finding which may also be relevant for clinical imaging of other hematological cancers.

116 ative of the European Academy of Allergy and Clinical Immunology (EAACI), experts from academia and r

117 The clinical implication was studied in blood samples of pat

118 tanding of human CSF flux and open important clinical implications, including concepts for drug deliv

119 obesity have potential short- and long-term clinical implications.

120 sgACC and the default mode network predicted clinical improvement, as did more positive amygdala-to-v

121 data are available, for patients with other clinical indications, including patients with diabetes m

122 Our pragmatic study avoided the clinical influences associated with prospective study in

123 CTCs are a minimally invasive source of clinical information that can be used to prognose patien

124 n this perspective, we analyze the available clinical information to document the natural history of

125 demonstrated increased adhesion forces for a clinical isolate compared with the lab strain.

126 ibility are available due to the scarcity of clinical isolates and difficulty in performing susceptib

127 ion rate of early oral SCC is a considerable clinical issue.

128 ELPS2B model is a quick accurate tool to aid clinical judgment of the risk of seizures in critically

129 iplinary process that incorporates available clinical, laboratory, imaging, and histological features

130 A set of 296, mostly XDR, clinical M. tuberculosis isolates from four countries we

131 dren had 339 OCT sessions over the course of clinical management (median number of OCT scans per eye,

132 s, understanding these processes may improve clinical management and public health disease control.

133 e concerning the microbiology, epidemiology, clinical manifestations of infection, treatment, and pub

134 he association between rs1801198 and MMA and clinical manifestations that are linked to a decreased a

135 Rigorous clinical monitoring was done before, during, and after t

136 ality, thereby addressing an important unmet clinical need.

137 body-related theranostics in preclinical and clinical oncologic settings.

138 ed to be relevant to the American Society of Clinical Oncology (ASCO) membership.

139 patial clues for promoting regeneration, the clinical outcome after nerve damage is frequently poor.

140 turnaround time, which leads to compromised clinical outcome and promotes the spread of antibiotic r

141 verexpression of MYST3 correlated with worse clinical outcome in estrogen receptor+ (ER+) breast canc

142 Improvement of clinical outcome mainly relies on the declaration of adv

143 les, and it has heterogeneous effects on the clinical outcome of P. falciparum infection.

144 el potential molecular target to improve the clinical outcome of severely burned patients.

145 h colorectal cancer was associated with poor clinical outcome, irrespective of HIF-1 In addition, LOX

146 associated with improved cerebral edema and clinical outcome.

147 cells (MCs) in the CNS, leading to improved clinical outcome.

148 udy is needed to assess safety and long-term clinical outcome.

149 Secondary end points included clinical outcomes (major adverse cardiac events), use of

150 Clinical outcomes and health care use through 6 months w

151 he dynamic wound microbiome is indicative of clinical outcomes and may be a valuable guide for person

152 We found no differences in clinical outcomes between MGUS patients and KT controls.

153 ructured to ensure that short- and long-term clinical outcomes continue to improve.

154 and 61.4 years for all HIV-exposed infants; clinical outcomes for truly infected infants did not dif

155 of AURKA overexpression associated with poor clinical outcomes have been attributed to increased cell

156 ease (ECD) is associated with less favorable clinical outcomes in patients with acute ischemic stroke

157 th brain atrophy (p.Ser94Arg) and extend the clinical outcomes to a more severe spectrum with infanti

158 Hazard ratios (HRs) for clinical outcomes were calculated for children with asth

159 trating the beneficial effects of statins on clinical outcomes, the mechanisms underlying these effec

160 riprocedural factors translating into poorer clinical outcomes.

161 acute ICH is safe and effective in improving clinical outcomes.

162 tically ill patients is associated with poor clinical outcomes.

163 search is needed on procedural and long-term clinical outcomes.

164 Clinical parameters were recorded at baseline and 3, 6,

165 onal polynomials showed similar responses in clinical parameters, inflammatory mediators, and proport

166 Despite broad improvements in clinical parameters, total bacteria and individual speci

167 way (ie, to dissect and stratify the complex clinical phenotype into more homogeneous subgroups based

168 The clinical phenotype ranges from the classical presentatio

169 these relationships were not affected by the clinical phenotype.

170 mmary, we present a method for prediction of clinical phenotypes using baseline genome-wide expressio

171 fication of genetic variants associated with clinical phenotypes.

172 B patients and corresponded with specific TB clinical phenotypes.

173 technology permitted detailed imaging of the clinical picture of unusual cases of XLRS.

174 We investigated 18 833 children with clinical pneumonia and identified 2156 cases of radiolog

175 A clinical point score was generated, and its diagnostic p

176 cally targeting prefusion F could have great clinical potential.

177 d to verify this hypothesis commonly used in clinical practice although it has not been prospectively

178 to discriminate between biologics to inform clinical practice and decision making.

179 d severity assessments that are feasible for clinical practice and epidemiological research.

180 risk score can be easily calculated in daily clinical practice and strongly correlated with mortality

181 biomarkers and/or amyloid PET assessment in clinical practice and trials.

182 and family-centered care to revise the 2007 Clinical Practice Guidelines for support of the family i

183 and facilitate its implementation in routine clinical practice in various settings and institutions w

184 pressure monitoring that is not feasible in clinical practice, and as such limits the generalizabili

185 urveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic

186 ide guidance on the appropriate use of CE in clinical practice.

187 RETATION: We developed and validated a novel clinical prediction model with good discriminative perfo

188 Clinical predictors included demographics, anthropometri

189 be estimated in patients with FH with simple clinical predictors.

190 l of bacteremia), in patients at the time of clinical presentation on IL-10 production and its associ

191 nal spectrum of this gene and the associated clinical presentation.

192 3,000, is characterized by a highly variable clinical presentation.

193 nal B prostate cancers exhibited the poorest clinical prognoses on both univariable and multivariable

194 o their emerging applications in continuous, clinical-quality health monitors and advanced, bioelectr

195 Clinical Question: Are different opioid agonist treatmen

196 relative to biopsies during virological and clinical quiescence.

197 all those who underwent (18)F-FDG PET/CT for clinical reasons at our institution before inclusion in

198 Prospective clinical registry with data collected from September 201

199 Collectively, our data support the clinical relevance of this protease in human influenza p

200 Despite its high clinical relevance, the evolutionary origin of USA300 re

201 Despite its clear clinical relevance, the neural circuitry governing the m

202 ese species and clades tend to be of limited clinical relevance, they could potentially serve as rese

203 iverse biological processes and are of great clinical relevance.

204 CLINICAL RELEVANCE: Relative safety of ranibizumab and b

205 The estimates of the model, the clinical report, and the three reviewers were within the

206 standardized methods for the conduct of TBM clinical research that were drafted at an international

207 h meeting organized by the Oxford University Clinical Research Unit in Vietnam.

208 on language and procedures are being used in clinical research.

209 aspect within 1 to 2 weeks of treatment, and clinical resolution of lesions within 2 months.

210 response to ART when effects on viremia and clinical response are not met.

211 The proportion of patients with complete clinical response at day 7 was significantly higher (P =

212 omen who received each elagolix dose met the clinical response criteria for the two primary end point

213 chromatin features that may be predictive of clinical response to epigenetic therapy.

214 ession and BCR surface density may influence clinical response to therapeutic inhibition of tonic BCR

215 biological cure on culture is a predictor of clinical response to treatment.

216 the clinical trial and correlated these with clinical response.

217 o pretreatment tumour burden correlated with clinical response.

218 onitored in an outpatient setting with daily clinical review and collection of blood and stool cultur

219 d the presence of hypoxia are the three main clinical risk factors and are more predictive of poor ou

220 lative contribution of social, biologic, and clinical risk factors to RSV mortality in low-income reg

221 ive model based on genetic risk, established clinical risk factors, and diagnostic biomarkers.

222 venting acute GVHD in settings of heightened clinical risk that use myeloablative conditioning, unrel

223 as been applied in research studies, but its clinical role has been limited by its lack of reproducib

224 Future research should aim to establish clinical, serological, and imaging biomarkers to identif

225 ial to accurately estimate visceral fat in a clinical setting.

226 Diagnosis in routine clinical settings is inadequate due to the low sensitivi

227 g a broad array of diseases and disorders in clinical settings worldwide.

228 ii are unlikely to be of diagnostic value in clinical settings.

229 by aesthesiometry, oedema by plethysmometry, clinical severity by scoring, joint function by grid tes

230 age of bleeding (hemostasis) is of paramount clinical significance in prophylactic, surgical, and eme

231 Although the clinical significance of these findings is yet to be det

232 Such differences may have clinical significance, as therapeutic targeting of a sig

233 rse events associated with smoking limit its clinical significance.

234 By using human clinical specimens, we also showed that miR-152 expressi

235 apparent temporal or dose-related changes in clinical status (specifically acute, Koch phenomenon-lik

236 n types of clinicians, and between patients' clinical status and mood.

237 Clinical status at last pediatric clinic visit prior to

238 BACKGROUND & AIMS: Clinical studies showed teduglutide to increase urine pr

239 al collaboration will be required to perform clinical studies to inform the treatment of these rare d

240 antages that make it particularly useful for clinical studies, including non-invasive collection, tem

241 ylation BeadChips has shown great utility in clinical studies, no equivalent tool is available for ro

242 anned, step-wise sequence of preclinical and clinical studies, to determine whether this class of pot

243 influenza vaccines cannot be determined from clinical studies.

244 tor 2 (PF-06263276), which was advanced into clinical studies.

245 patients had a higher likelihood of complete clinical success (OR 0.95 per extra year, 0.93-0.98; p<0

246 This study was performed in a clinical/surgical setting at Retina Consultants of Houst

247 ents with newly diagnosed cardiomyopathy and clinical suspicion of myocarditis.

248 results of PET imaging is a valid marker of clinical symptoms and neurodegeneration.

249 partially be explained by sex differences in clinical symptoms, etiological models suggest that the b

250 of major functional disability, with minimal clinical symptoms.

251 es for a limited time but without noticeable clinical symptoms.

252 inical model, establishing the rationale for clinical testing.

253 Clinical tests that evaluate the sense of smell face two

254 Two fundamental challenges plague clinical translation of vaccine-adjuvants: reducing acut

255 ng nucleic acids therapeutics for successful clinical translation.

256 There were clinical trends in permanent stoma rates and anastomotic

257 tions in sequential patient samples from the clinical trial and correlated these with clinical respon

258 e or had no financial coverage for ASCT in a clinical trial and instead received melphalan at 200 mg/

259 atelet Inhibition [PLATFORM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standa

260 BENEFIT was a randomized clinical trial comparing early versus delayed interferon

261 Although clinical trial design is challenging, due in part to a l

262 Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angi

263 viduals (SWIFT-C) is an open-label, 2-cohort clinical trial in which the first cohort assessed for th

264 inic keratosis in a randomized, double-blind clinical trial involving 131 participants.

265 Four-group cluster randomized clinical trial of mothers of healthy term newborns who w

266 Dutch Clinical Trial Registration no: NL30551.068.09.

267 (A Clinical Trial to Demonstrate the Efficacy of Cangrelor

268 A randomized clinical trial was conducted from February 1 to August 3

269 is parallel-design, double-blind, randomized clinical trial, called Resveratrol to Improve Outcomes i

270 A multicenter phase 2 randomized clinical trial, the Arginine Deiminase and Mesothelioma

271 eater than perhaps the strongest adjuvant in clinical trials (that is, CpG in Montanide).

272 omarkers to identify high-risk patients, and clinical trials evaluating novel therapies should be foc

273 lysine demethylase 1 inhibitor currently in clinical trials for the treatment of small cell lung car

274 ans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV.

275 However, clinical trials have produced inconsistent results.

276 ge in licensing, we review the outcomes from clinical trials in children with persistent AA receiving

277 ensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.

278 nsensus Development Projects on Criteria for Clinical Trials in Chronic GVHD standardized the termino

279 or treating NASH and underscore the need for clinical trials in this area.

280 Randomized clinical trials in which self-guided iCBT was compared w

281 of Parkinson's disease, which may be used in clinical trials of disease-modifying therapies.

282 Pragmatic clinical trials of terlipressin with albumin are warrant

283 Among the phase III clinical trials only the RV144 vaccine trial elicited si

284 -analysis and create a network of randomized clinical trials to compare outcomes after specific treat

285 Two clinical trials to define novel ways of using an existin

286 ied 1536 samples obtained from 3 independent clinical trials with drisapersen, an antisense oligonucl

287 -based therapies have been tested in phase I clinical trials, a quarter of which have reached phase I

288 RSV entry blockers are in clinical trials, but escape mutations challenge their po

289 ystematic reviews, meta-analyses, randomized clinical trials, prospective comparative observational s

290 nsion (PAH) is hampered by lack of pediatric clinical trials.

291 and several other compounds are in advanced clinical trials.

292 tch protein activity have already moved into clinical trials.

293 ficacy have been extensively demonstrated in clinical trials; however, its performance in routine hea

294 ing PET ligand with a half-life suitable for clinical use outside of the research setting.

295 value for major bleeding leading to improved clinical usefulness compared to the original scores.

296 used decision-curve analysis to evaluate the clinical usefulness of each score and the primary outcom

297 tabilizing DNA-cleavage complexes, but their clinical utility has been compromised by resistance.

298 novel predictive score is needed to confirm clinical utility.

299 unmet needs as well as the prerequisites for clinical validation.

300 in controlling cCMV-related disease and the clinical value of this marker as a predictor of long-ter